Intraperitoneal administration of biocompatible hyaluronic acid hydrogel containing multi-chemotherapeutic agents for treatment of colorectal peritoneal carcinomatosis.
Animals
Antineoplastic Agents
/ administration & dosage
Biocompatible Materials
/ chemistry
Carcinoma
/ drug therapy
Cell Line, Tumor
Colorectal Neoplasms
/ drug therapy
Drug Delivery Systems
/ methods
Female
Humans
Hyaluronic Acid
/ administration & dosage
Hydrogels
/ administration & dosage
Injections, Intraperitoneal
/ methods
Liver Neoplasms
/ drug therapy
Lung Neoplasms
/ drug therapy
Male
Mice
Mice, Inbred BALB C
Peritoneal Neoplasms
/ drug therapy
Rats
Rats, Sprague-Dawley
Cisplatin
Colorectal peritoneal carcinomatosis
Hyaluronic acid
Hydrogel
Microsphere
Paclitaxel
Journal
International journal of biological macromolecules
ISSN: 1879-0003
Titre abrégé: Int J Biol Macromol
Pays: Netherlands
ID NLM: 7909578
Informations de publication
Date de publication:
01 Jun 2020
01 Jun 2020
Historique:
received:
20
07
2019
revised:
29
02
2020
accepted:
29
02
2020
pubmed:
4
3
2020
medline:
4
2
2021
entrez:
4
3
2020
Statut:
ppublish
Résumé
Colorectal peritoneal carcinomatosis (CRPC) is an advanced stage of colorectal cancer (CRC), which significantly decreases patient survival and quality of life. Here, the naturally occurring polysaccharide hyaluronic acid (HA) was used to prepare an injectable hydrogel and simultaneously deliver 5-fluorouracil (5-FU), cisplatin (DDP) and paclitaxel (PTX) microspheres for intraperitoneal CRPC chemotherapy. The drug-loaded HA hydrogel released the drugs in a sustained manner, and showed low toxicity both in vitro and in a mouse model of CRPC. Furthermore, direct injection of the drug-loaded HA hydrogel in the abdominal cavity of tumor-bearing mice significantly decreased tumor growth and liver/lung metastasis, along with decreasing the volume of ascites and inhibiting local intestinal infiltration of the tumor cells. Therefore, this novel multi-drug hydrogel delivery system may effectively clear CRPC tumors without any adverse effects when used in intraperitoneal chemotherapy.
Identifiants
pubmed: 32126201
pii: S0141-8130(19)35638-7
doi: 10.1016/j.ijbiomac.2020.02.326
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Biocompatible Materials
0
Hydrogels
0
Hyaluronic Acid
9004-61-9
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
718-726Informations de copyright
Copyright © 2020. Published by Elsevier B.V.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare no conflict of interest.